Influenza Immunization
Conditions
Brief summary
This is a Phase 1, parallel, randomized, active-controlled, multi-center, dose-esclation study with a Master Protocol design which will include several substudies that are developed to evaluate the safety and immunogenicity of different dose levels of modified messenger ribonucleic acid (mRNA) vaccines encoding full length hemagglutinin (HA) sequence of influenza virus encapsulated in lipid nanoparticles (LNPs) (hereafter referred to as HA mRNA vaccines) compared to control(s). The HA mRNA vaccine candidates and control(s) are presented in the substudy protocols. The aim is to generate clinical data across different substudies to provide learnings regarding the mRNA technology to support optimization of the mRNA platform including mRNA and LNP design and to support the decision of LNP and dose selection for future projects using mRNA technology. The purpose of this Substudy 01 is to evaluate the safety and immunogenicity of a single IM injection of up to 5 dose levels of a monovalent modified mRNA encoding the full-length HA sequence of A/Tasmania/503/2020 (H3N2) influenza virus encapsulated in LNP (hereafter referred to as H3 mRNA /LNP) administered as a single intramuscular (IM) injection in adults 18 to 49 years of age and 60 years of age and above, compared to the following active control: a quadrivalent recombinant influenza vaccine (RIV4).
Detailed description
The study duration per participant will be approximately 6 months with 1 injection of one of the different HA mRNA vaccines or control for each substudy and a dose-escalation with sequential enrollment (sentinel cohort followed by main cohort).
Interventions
BIOLOGICALH3 mRNA / LNP Vaccine
Pharmaceutical Form: Suspension for injection Route of Administration: Intra-Muscular
Pharmaceutical Form: Solution for injection in a pre-filled syringe Route of Administration: Intra-Muscular
Sponsors
Sanofi Pasteur, a Sanofi Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Masking description
This study will be blinded to participants and sites (except for those preparing/administering study interventions. The sponsor will be unblinded.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Aged 18 years and above on the day of inclusion \*Aged 18 years to 49 years or 60 years and above on the day of inclusion (substudy 01) * A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: * Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile. OR • Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration. * A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) at the screening visit. * Inclusion Criteria to be Checked at Visit 1 (Day 1) Participants are eligible for the study only if all of the following criteria are met: A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies: • Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile. OR • Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration. A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours before the first dose of study intervention.
Exclusion criteria
* Previous vaccination against influenza in the previous 6 months with an investigational or marketed vaccine * Any screening laboratory parameter with laboratory abnormalities that are greater than Grade 1 or deemed clinically significant in the opinion of the Investigator * OR, any screening Liver Function Test (ALT, AST, Bilirubin) \> 1.2x Upper Limit of Normal or any other screening laboratory parameter outside of the range of normal limits for age and gender * Positive test for human immunodeficiency virus (HIV) antigen and/or antibodies (Abs), hepatitis B (HB) virus surface antigen (HBsAg), hepatitis B core antibodies (HBcAb), or hepatitis C virus antibodies (HCV Abs) * Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) * Known systemic hypersensitivity to any of the study intervention components (eg, polyethylene glycol \[PEG\], polysorbate); history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances; any allergic reaction (eg, anaphylaxis) after administration of mRNA COVID-19 vaccine * Previous history of myocarditis, pericarditis, and/or myopericarditis * Screening electrocardiogram (ECG) or troponin value that is consistent with probable or possible myocarditis, pericarditis, and/or myopericarditis or screening ECG that demonstrates clinically relevant abnormalities that may affect participant safety or study results * Self-reported thrombocytopenia, contraindicating intramuscular vaccination based on Investigator's judgment * Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination based on Investigator's judgment * Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with study conduct or completion * Alcohol, prescription drug, or substance abuse that, in the opinion of the Investigator, might interfere with the study conduct or completion * Receipt of any vaccine in the 4 weeks preceding study enrollment or planned receipt of any vaccine in the 4 weeks following study intervention administration * Receipt of any mRNA vaccine/product in the 2 months preceding study enrollment or planned receipt of any mRNA vaccine/product within the 2 months following study intervention administration * Receipt of immune globulins, blood or blood-derived products in the past 3 months -Participation at the time of study enrollment (or in the 4 weeks preceding study enrollment or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure * Previous vaccination against influenza in the previous 6 months with an investigational or marketed vaccine *
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with immediate adverse events (AEs) | Within 30 minutes after vaccination | Unsolicited systemic AEs that occur within 30 minutes after vaccination |
| Number of participants with solicited injection site or systemic reaction | Within 7 days from vaccination | Number of participants reporting Adverse reactions pre-listed in the protocol and case report form (CRF) * Injection site reactions: pain, redness, swelling * Systemic reactions: fever, headache, malaise, myalgia, arthralgia, chills |
| Number of participants with unsolicited adverse events | Up to 28 days after injection | Unsolicited (spontaneously reported) adverse events not fulfilling criteria for solicited reactions |
| Presence of out-of-range biological test results | At Day 3, Day 9 or Day 29 | Number of participants with biological safety assessment values out of normal range (as per the laboratory performing the test) |
| Presence of serious adverse events (SAEs) | Throughout Study (up to approximately Month 6) | Number of participants experiencing SAEs |
| Presence of adverse events of special interest (AESIs) | Throughout Study (up to approximately Month 6) | Number of participants experiencing AESIs |
| Hemagglutination inhibition (HAI) antibody (Ab) response to homologous strain | Day 29 | Antibody are expressed as geometric mean titers (GMTs) at baseline and post-baseline |
| HAI titers at D01 | Day 1 | Antibody titers are expressed as GMTs at baseline and post-baseline |
| HAI titers at D29 | Day 29 | Antibody titers are expressed as GMTs at baseline and post-baseline |
| Individual HAI Ab titer ratio | Day 1 through Day 29 | Individual HAI Ab titer ratio will be calculated as: D29/D01 |
| Number of Participants with Vaccine Response or Seroconversion | Day 1 through Day 29 | Seroconversion (HAI Ab titer \< 10 \[1/dil\] at D01 and post-injection titer ≥ 40 \[1/dil\] at D29, or titer ≥ 10 \[1/dil\] at D01 and a ≥ 4-fold increase in titer \[1/dil\] at D29) |
| 2-fold and 4-fold rise in HAI titers from D01 to D29 | Day 1 to Day 29 | Expressed as percentage post-baseline |
| Percentage of participants with detectable antibody HAI titers greater than or equal to (≥) 40 [1/dil] | Day 29 | — |
| Geometric Mean Titers (GMTs) of neutralizing antibody (nAb) titers at Day 1 | Day 1 | Nab titers at Day 1 |
| Geometric Mean Titers (GMTs) of neutralizing antibody (nAb) titers at Day 29 | Day 29 | Nab titers at Day 29 |
| Individual nab titer ratio | Day 1 through Day 29 | Individual nab titer ratio will be calculated as: D29/D01 |
| 2-fold and 4-fold increase in neutralizing Ab titers from D01 to D29 | Day 1 to Day 29 | Expressed as percentage post-baseline |
Countries
Australia, United Kingdom
Outcome results
None listed